Orameds oral insulin candidate fails to meet phase 3 targets
By, Admin1 min read
Share
Oramed Pharmaceuticals (Oramed) has said that it expects to discontinue its oral insulin clinical activities for type 2 diabetes after a phase 3 trial of its oral insulin candidate, ORMD-0801, produced
Found this useful? Share it with your team.
Newsletter
Stay ahead with Clival insights
Subscribe to get the latest updates, data releases and industry information — straight to your inbox.
